Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX

Phase 3

• Conditions: NSTEMI; Acute Coronary Syndromes; STEMI
• Interventions: Other: trans-femoral and standard of care pharmacology; Other: trans-radial and short-term bivalirudin; Other: trans-radial and long-term bivalirudin infusion; Other: trans-radial and standard of care pharmacology; Other: Trans-femoral and Short-term bivalirudin; Other: trans-femoral and long-term bivalirudin infusion

• Registration Number: NCT01433627
• Lead Sponsor: Italian Society of Invasive Cardiology

Brief Summary

This protocol describes a study to compare intended trans-radial versus trans-femoral intervention and bivalirudin monotherapy versus current European standard of care consisting of unfractionated heparin (UFH) plus provisional use of glycoprotein IIb/IIIa inhibition via the use of one of the three available agents on the market (e.g. abciximab, tirofiban or eptifibatide) in patients (≥18 years) with ACS, that are intended for an invasive management strategy. This study will be conducted in compliance with Good Clinical Practices (GCP) including the Declaration of Helsinki and all applicable regulatory requirements.

Detailed Description

The use of combined antithrombotic therapies over the last two decades has decreased the risk of a heart attack after percutaneous coronary intervention substantially but has also been associated with a significant increase in bleeding risk. Therapies or strategies that maintain the benefits seen with currently available antithrombotic therapies but which have lower bleeding risk are therefore of great clinical importance. Indeed, major bleeding is currently the most common non-cardiac complication of therapy for patients with coronary artery disease who have undergone percutaneous coronary intervention (PCI).

Bleeding in patients with acute coronary syndrome (ACS) is associated with an increased risk of long term mortality and morbidity, and this relationship is currently thought to be causal. Therefore' reducing the frequency of bleeding events while maintaining efficacy is an important goal in the management of patients with ACS. The most common site of bleeding in invasively managed patients with ACS is at the femoral artery puncture site used for heart catheterization

The MATRIX study is a multi-centre, prospective, randomised, open-label, 2 by 2 factorial comparison of trans-radial vs. trans-femoral intervention and bivalirudin vs. unfractionated heparin and provisional use of glycoprotein IIb/IIIa inhibitor.

Objectives:

1. To demonstrate that trans-radial intervention as compared to femoral access site is associated to lower rate of the composite endpoint of death, MI or stroke within the first 30 days after randomization in acute coronary syndrome patients undergoing early invasive management.

2. To demonstrate that bivalirudin infusion as compared to standard of care therapy consisting of unfractionated heparin and provisional use of glycoprotein IIb/IIIa inhibitors are associated to lower rate of the composite endpoint of death, MI or stroke within the first 30 days after randomization in acute coronary syndrome patients undergoing early invasive management.

Patients randomly assigned to receive bivalirudin will be randomized to stop bivalirudin infusion at the end of PCI or to prolong bivalirudin at an infusion rate of 0.25 mg/kg/hour for at least 6 hours after completion of PCI. The primary hypothesis in this sub-randomization is that prolonged post-intervention bivalirudin infusion will be superior to no bivalirudin post-PCI infusion with respect to the net composite outcome consisting of any death, MI, stroke, urgent TVR, stent thrombosis and BARC-defined type 3 and 5 bleeding events within 30 days. Secondary objectives for the sub-randomization of prolonged bivalirudin versus no post-PCI infusion in the bivalirudin group will consist of each component of the primary composite endpoint through the entire follow-up duration

Study Timeline

• Study First Submitted: 2011-09-12
• Study First Submitted QC: 2011-09-13
• Study First Posted: 2011-09-14
• Study Start: 2011-10
• Primary Completion: 2014-11
• Status Verified: 2015-01
• Last Update Submitted: 2015-01-28
• Last Update Posted: 2015-01-29
• Study Completion: 2015-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 7200

Inclusion Criteria

NSTEACS definition: Patients with all of the following criteria will be eligible:

1. history consistent with new, or worsening ischemia, occurring at rest or with minimal activity;
2. enrollment within 7 days of the most recent symptoms;
3. planned coronary angiography with possible indication to PCI;
4. at least 2 of the following criteria: 1. Aged 60 years or older, 2. Troponin T or I or creatine kinase MB above the upper limit of normal; 3. Electrocardiograph changes compatible with ischemia, ie, ST depression of 1 mm or greater in 2 contiguous leads, T-wave inversion more than 3 mm, or any dynamic ST shifts;

STEMI definition: i) chest pain for >20 min with an electrocardiographic ST-segment elevation ≥1 mm in two or more contiguous electrocardiogram (ECG) leads, or with a new left bundle-branch block, or an infero-lateral myocardial infarction (MI) with ST segment depression of ≥1 mm in ≥2 of leads V1-3 with a positive terminal T wave and ii) admission either within 12 h of symptom onset or between 12 and 24 h after onset with evidence of continuing ischemia or previous lytic treatment.

Exclusion Criteria

1. Patients who can not give informed consent or have a life expectancy of <30 days
2. Allergy/intolerance to Bivalirudin or unfractionated heparin.
3. Stable or silent CAD as indication to coronary angiography
4. Treatment with LWMH within the past 6 hours
5. Treatment with any GPI in the previous 3 days
6. Absolute contraindications or allergy that cannot be pre-medicated to iodinated contrast or to any of the study medications including aspirin or clopidogrel.
7. Contraindications to angiography, including but not limited to severe peripheral vascular disease.
8. If it is known pregnant or nursing mothers. Women of child-bearing age will be asked if they are pregnant or think that they may be pregnant.
9. If it is known a creatinine clearance <30 mL/min or dialysis dependent.
10. Previous enrollment in this study.
11. Treatment with other investigational drugs or devices within the 30 days preceding
12. Randomisation or planned use of other investigational drugs or devices in this trial.
13. Severe uncontrolled hypertension (defined as persistent systolic blood pressure higher than 220 mmHg despite medical treatment).
14. Subacute bacterial endocarditis
15. PCI in the previous 30 days

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
trans-femoral and standard of care pharmacology	trans-femoral and standard of care pharmacology	Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
trans-radial and short-term Bivalirudin	trans-radial and short-term bivalirudin	Patients will be randomized to receive a trans-radial intervention and concomitant bivalirudin infusion. bivalirudin will be stopped at the end of PCI.
trans-radial and long-term bivalirudin	trans-radial and long-term bivalirudin infusion	Trans-radial intervention: will be performed according to institutional guidelines and established local practice. Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group.
trans-radial and standard of care pharmacology	trans-radial and standard of care pharmacology	Trans-radial intervention: will be performed according to institutional guidelines and established local practice. unfractionated heparin (UFH) which may be followed by the addition of a glycoprotein IIb/IIIa inhibitor
trans-femoral and short-term bivalirudin	Trans-femoral and Short-term bivalirudin	Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI.
Trans-femoral and long-term bivalirudin	trans-femoral and long-term bivalirudin infusion	Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group.

Primary Outcome Measures

Name	Time	Method
the composite of Death, non-fatal myocardial infarction or stroke	30 days	To demonstrate in ACS patients undergoing an early invasive management, i.e. diagnostic coronary angiogram+PCI or ad hoc planned PCI that trans-radial intervention as compared to femoral access site is associated to lower rate of the composite endpoint of death, MI or stroke within the first 30 days after randomization.
The composite of death, non-fatal myocardial infarction or stroke	30 days	To demonstrate that in an ACS patients with an intended PCI treatment strategy or in whom upstream treatment was felt necessary by local investigators the use of bivalirudin as compared to unfractionated heparin (UFH) plus or minus Glycoprotein IIb/IIIa inhibitor (GPI) is associated to lower rate of the composite endpoint of death, MI or stroke within the first 30 days after randomization.
Death, non-fatal myocardial infarction, stroke, stent thrombosis or BARC-defined type 3 or 5 bleedings	30 days	The primary hypothesis of this sub-randomization is that prolonged post-intervention bivalirudin infusion (long bivalirudin arm) will be superior to peri-PCI bivalirudin infusion only (short bivalirudin arm) with respect to the net composite outcomes consisting of any death, MI, stroke, stent thrombosis or BARC-defined type 3 and 5 bleeding events within 30 days.

Secondary Outcome Measures

Name	Time	Method
the composite endpoint of death, MI, stroke or BARC-defined type 3 and 5 major bleeding complications	30 days	Key secondary objective: To demonstrate that trans-radial intervention as compared to femoral access site is associated to lower rate of the composite endpoint of death, MI, stroke or BARC-defined type 3 and 5 major bleeding complications within the first 30 days after randomization.
Death, non-fatal MI, stroke or BARC-defined type 3 and 5 major bleeding	30 days	To demonstrate that use of bivalirudin as compared to unfractionated heparin (UFH) plus or minus Glycoprotein IIb/IIIa inhibitor (GPI) is associated to lower rate of the composite endpoint of death, MI, stroke or BARC-defined type 3 and 5 major bleeding complications within the first 30 days after randomization.

Trial Locations

Locations (61)

Azienda Ospedaliera Pugliese Ciaccio - Catanzaro; 🇮🇹 Catanzaro, Calabria, Italy

Ospedale San Camillo di Roma; 🇮🇹 Roma, Lazio, Italy

Policlinico Casilino; 🇮🇹 Roma, Lazio, Italy

A.O. Civili Riuniti - Giovanni Paolo II; 🇮🇹 Sciacca, Sicily, Italy

Ospedale Civile di Mirano; 🇮🇹 Mirano, Veneto, Italy

Ospedale G. B. Morgagni; 🇮🇹 Forlì, Emilia Romagna, Italy

Ospedale Clinicizzato SS Annunziata di Chieti; 🇮🇹 Chieti, Abruzzo, Italy

Azienda Ospedaliera Monaldi; 🇮🇹 Napoli, Campania, Italy

Azienda Ospedaliera S. Maria della Misericordia di Udine; 🇮🇹 Udine, Friuli Venezia Giulia, Italy

Ospedale Sacra Famiglia; 🇮🇹 Erba, Lombardia, Italy

A.O: Fatebenefratelli e oftalmico; 🇮🇹 Milano, Lombardia, Italy

IRCCS Multimedica; 🇮🇹 Sesto San Giovanni, Lombardia, Italy

A. O. Ospedale Civile di Vimercate; 🇮🇹 Vimercate, Lombardia, Italy

Città di Lecce Ospedale (GVM); 🇮🇹 Lecce, Puglia, Italy

Ospedale Vito Fazzi; 🇮🇹 Lecce, Puglia, Italy

IRCCS Ospedale Casa Sollievo della Sofferenza; 🇮🇹 San Giovanni Rotondo, Puglia, Italy

A.O. Treviglio; 🇮🇹 Treviglio, Lombardia, Italy

Casa di Cura Villa Verde; 🇮🇹 Taranto, Puglia, Italy

Maria Cecilia Hospital; 🇮🇹 Cotignola, RA, Italy

Azienda USL Sirai; 🇮🇹 Carbonia, Sardegna, Italy

Ospedale San Francesco; 🇮🇹 Nuoro, Sardegna, Italy

A. O. Universitaria Policlinico V. Emanuele Ferrarotto; 🇮🇹 Catania, Sicilia, Italy

Ospedale Umberto I di Siracusa; 🇮🇹 Siracusa, Sicilia, Italy

Ospedale S. Vincenzo; 🇮🇹 Taormina, Sicilia, Italy

Azienda Ospedaliera Universitaria Pisana; 🇮🇹 Pisa, Toscana, Italy

Azienda USL - Grosseto; 🇮🇹 Grosseto, Toscana, Italy

Università Campus Bio-Medico di Roma; 🇮🇹 Rome, Italy

Azienda Ospedaliera di Desio e Vimercate - P.O. di Desio; 🇮🇹 Desio, Lombardia, Italy

Azienda Ospedaliero-Universitaria "Maggiore della Carità"; 🇮🇹 Novara, Piemonte, Italy

Azienda Ospedaliera San Salvatore; 🇮🇹 Pesaro, Marche, Italy

P.O. Zona Aretina-Ospedale San Donato; 🇮🇹 Arezzo, Toscana, Italy

Presidio Ospedaliero di Este; 🇮🇹 Este, Veneto, Italy

Ospedale Mater Salutis di Legnago; 🇮🇹 Legnago, Veneto, Italy

Ospedale S. Croce e Carlo; 🇮🇹 Cuneo, Piemonte, Italy

Ospedale San Giovanni Bosco; 🇮🇹 Torino, Piemonte, Italy

Villa Maria Eleonora Hospital; 🇮🇹 Palermo, Sicilia, Italy

Policlinico San Marco; 🇮🇹 Zingonia, Lombardia, Italy

A. O. Universitaria San Luigi Gonzaga di Orbassano; 🇮🇹 Orbassano, Piemonte, Italy

A.O. G. Mazzoni; 🇮🇹 Ascoli Piceno, Marche, Italy

A.O. Sandro Pertini; 🇮🇹 Roma, Lazio, Italy

Policlinico Sant'Orsola Malpighi; 🇮🇹 Bologna, Emilia Romagna, Italy

University Hospital of Ferrara; 🇮🇹 Ferrara, Emilia Romagna, Italy

Spedali Civili di Brescia; 🇮🇹 Brescia, Lombardia, Italy

Azienda Ospedaliera Sant'Anna di Como; 🇮🇹 Como, Lombardia, Italy

Ospedale del Cuore "G. Pasquinucci" Massa; 🇮🇹 Massa Carrara, Toscana, Italy

Presidio Ospedaliero Santa Chiara; 🇮🇹 Trento, Trentino Alto Adige, Italy

Ospedale Santa Maria Goretti; 🇮🇹 Latina, Lazio, Italy

Azienda Ospedaliera Universitaria "San Martino"; 🇮🇹 Genova, Liguria, Italy

Ospedale degli Infermi; 🇮🇹 Rivoli, TO, Italy

Azienda Ospedaliera Universitaria Ospedali Riuniti; 🇮🇹 Trieste, Friuli Venezia Giulia, Italy

Istituto Clinico Humanitas IRCCS; 🇮🇹 Rozzano, MI, Italy

Ospedali Riuniti ASL 17; 🇮🇹 Savigliano, Piemonte, Italy

A.O. Universitaria Molinette San Giovanni Battista; 🇮🇹 Torino, Piemonte, Italy

A.O. AORN Cardarelli; 🇮🇹 Napoli, Campania, Italy

Policlinico Federico II; 🇮🇹 Napoli, Campania, Italy

Ospedale del Santo Spirito in Sassia; 🇮🇹 Roma, Lazio, Italy

Azienda S. Maria Nuova di Reggio Emilia; 🇮🇹 Reggio Emilia, Emilia Romagna, Italy

Ospedale Civile Santo Spirito; 🇮🇹 Pescara, Abruzzo, Italy

Ospedale di Lodi; 🇮🇹 Lodi, Lombardia, Italy

Ospedale Di Venere - ASL Bari; 🇮🇹 Bari, Puglia, Italy

Ospedale Villa Scassi; 🇮🇹 Genova, Liguria, Italy